About WoundForce™

Technology

The IP-protected, novel formulation for WoundForce™ is based on the ability of the product’s active pharmaceutical ingredient – urea – to disaggregate and denature various types of necrotic material, which is then encapsulated and wicked away from the wound by a gentle detergent with a high affinity for this type of material. The formulation is further enhanced by a physiological buffer and hydrocolloidal base to promote an optimal environment within the wound bed.

Because the action of the drug is not based on enzymes, it does not have limitations common to those forms of products such as reduced efficacy outside of a narrow pH range, reduced efficacy related to interactions with common wound antimicrobials, and limited range of utility only on specific necrotic material types. This should give caregivers and patients alike the confidence they need in the efficacy of the drug, regardless of the varying conditions surrounding the wound.

This drug has not yet been approved by the FDA

3-Step Mode of Action

The Problem

Chronic wounds often have necrotic material made up of soft and hard eschar
(an aggregate of denatured proteins), which must be removed for chronic wounds to heal.

The Solution

1

A low concentration of urea selectively disentangles aggregated proteins that form the various types of necrotic material (including fibrin, elastin and collagen)

2

HECAMEG – a gentle zwitterionic detergent – envelopes the disentangled proteins

3

Wound exudate and/or cleansing solution dilutes and breaks the HECAMEG micelles, releasing the eschar proteins and moving them away from the wound bed.

WoundForce™ is a broad-spectrum topical drug candidate, whose formulation is protected by a pending patent. Key claims regarding the mechanism of action are reported above.

Opportunity

Disrupting a Monopoly Market

The standard of care, Santyl, is a monopoly drug with ~$320m in revenue, within a $1.1b market opportunity.

In-vitro and porcine data indicate that WoundForce™
is has a broader spectrum
and fewer contra indications than Santyl.

WoundForce™ will
capture market share by
disrupting competition
while also expanding
the market.

Santyl

is currently the only FDA-approved drug for wound debridement:a monopoly worth $320m in sales.

2018 REVENUE

˜$320

100%

MARKET SHARE

Santyl’s

usage (and market opportunity) is limited by pH range efficacy and non-compatibility with common antimicrobials.

MARKET POTENTIAL

SANTYL

UNTAPPED
DEMAND

$1.1B

31.8%

MARKET PENETRATION

WoundForce™ fills a huge market gap, by providing a more effective clinical solution that does not have the same usage limitations as Santyl, according to pre-clinical studies.

WoundForce™ targets a $1.1B market in which Santyl is the only player and has captured just one third of the opportunity.

6.5M
wounds

Burns

1.4 M

Venous Ulcers

0.7 M

Diabetic Foot Ulcers

1.6 M

Pressure Ulcers

2.8 M

WOUND DEMOGRAPHICS IN THE US